APO RESEARCH · REPORT
Sickle Cell Anemia Therapeutics
Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).
Product & engineering
Understand the product.
Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).
Selected research
Industry Research
Sickle Cell Anemia Therapeutics Industry Research Report 2026
Market perspective
Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).
Global Sickle Cell Anemia Therapeutics key players include Emmaus Medical, Addmedica, Gamida Cell, GlycoMimetics, etc.
Americas is the largest market, with a share about 55%, followed by Europe, and Middle East & Africa, both have a share over 35 percent.
Read the full market overview
In terms of product, Blood Transfusion is the largest segment, with a share over 35%. And in terms of application, the largest application is Child, followed by Adult.
Report Scope
This report quantifies the global Sickle Cell Anemia Therapeutics market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Sickle Cell Anemia Therapeutics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Sickle Cell Anemia Therapeutics Market by Company
Emmaus Medical
Addmedica
Gamida Cell
GlycoMimetics
Pfizer
Novartis
Global Blood Therapeutics
Micelle BioPharma
Bluebird Bio
Prolong Pharmaceuticals
Modus Therapeutics
Sangamo Biosciences
Bioverativ
Imara
Ironwood Pharmaceuticals
Sickle Cell Anemia Therapeutics Segment by Type
Blood Transfusion
Pharmacotherapy
Bone Marrow Transplant
Sickle Cell Anemia Therapeutics Segment by Application
Child
Adult
Sickle Cell Anemia Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sickle Cell Anemia Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sickle Cell Anemia Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sickle Cell Anemia Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Sickle Cell Anemia Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Blood Transfusion
- Pharmacotherapy
- Bone Marrow Transplant
Applications
- Child
- Adult
Companies covered
- Emmaus Medical
- Addmedica
- Gamida Cell
- GlycoMimetics
- Pfizer
- Novartis
- Global Blood Therapeutics
- Micelle BioPharma
- Bluebird Bio
- Prolong Pharmaceuticals
- Modus Therapeutics
- Sangamo Biosciences
- Bioverativ
- Imara
- Ironwood Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Sickle Cell Anemia Therapeutics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Blood Transfusion
- 2.2.3 Pharmacotherapy
- 2.2.4 Bone Marrow Transplant
- 2.3 Sickle Cell Anemia Therapeutics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Child
- 2.3.3 Adult
- 2.4 Assumptions and Limitations
3 Sickle Cell Anemia Therapeutics Breakdown Data by Type
- 3.1 Global Sickle Cell Anemia Therapeutics Historic Market Size by Type (2021-2026)
- 3.2 Global Sickle Cell Anemia Therapeutics Forecasted Market Size by Type (2027-2032)
4 Sickle Cell Anemia Therapeutics Breakdown Data by Application
- 4.1 Global Sickle Cell Anemia Therapeutics Historic Market Size by Application (2021-2026)
- 4.2 Global Sickle Cell Anemia Therapeutics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Sickle Cell Anemia Therapeutics Market Perspective (2021-2032)
- 5.2 Global Sickle Cell Anemia Therapeutics Growth Trends by Region
- 5.2.1 Global Sickle Cell Anemia Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Sickle Cell Anemia Therapeutics Historic Market Size by Region (2021-2026)
- 5.2.3 Sickle Cell Anemia Therapeutics Forecasted Market Size by Region (2027-2032)
- 5.3 Sickle Cell Anemia Therapeutics Market Dynamics
- 5.3.1 Sickle Cell Anemia Therapeutics Industry Trends
- 5.3.2 Sickle Cell Anemia Therapeutics Market Drivers
- 5.3.3 Sickle Cell Anemia Therapeutics Market Challenges
- 5.3.4 Sickle Cell Anemia Therapeutics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Sickle Cell Anemia Therapeutics Players by Revenue
- 6.1.1 Global Top Sickle Cell Anemia Therapeutics Players by Revenue (2021-2026)
- 6.1.2 Global Sickle Cell Anemia Therapeutics Revenue Market Share by Players (2021-2026)
- 6.2 Global Sickle Cell Anemia Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Sickle Cell Anemia Therapeutics Head Office and Area Served
- 6.4 Global Sickle Cell Anemia Therapeutics Players, Product Type & Application
- 6.5 Global Sickle Cell Anemia Therapeutics Manufacturers Established Date
- 6.6 Global Sickle Cell Anemia Therapeutics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Sickle Cell Anemia Therapeutics Market Size (2021-2032)
- 7.2 North America Sickle Cell Anemia Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Sickle Cell Anemia Therapeutics Market Size by Country (2021-2026)
- 7.4 North America Sickle Cell Anemia Therapeutics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Sickle Cell Anemia Therapeutics Market Size (2021-2032)
- 8.2 Europe Sickle Cell Anemia Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Sickle Cell Anemia Therapeutics Market Size by Country (2021-2026)
- 8.4 Europe Sickle Cell Anemia Therapeutics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Sickle Cell Anemia Therapeutics Market Size (2021-2032)
- 9.2 Asia-Pacific Sickle Cell Anemia Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Sickle Cell Anemia Therapeutics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Sickle Cell Anemia Therapeutics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Sickle Cell Anemia Therapeutics Market Size (2021-2032)
- 10.2 South America Sickle Cell Anemia Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Sickle Cell Anemia Therapeutics Market Size by Country (2021-2026)
- 10.4 South America Sickle Cell Anemia Therapeutics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Sickle Cell Anemia Therapeutics Market Size (2021-2032)
- 11.2 Middle East & Africa Sickle Cell Anemia Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Emmaus Medical
- 12.1.1 Emmaus Medical Company Information
- 12.1.2 Emmaus Medical Business Overview
- 12.1.3 Emmaus Medical Revenue in Sickle Cell Anemia Therapeutics Business (2021-2026)
- 12.1.4 Emmaus Medical Sickle Cell Anemia Therapeutics Product Portfolio
- 12.1.5 Emmaus Medical Recent Developments
- 12.2 Addmedica
- 12.2.1 Addmedica Company Information
- 12.2.2 Addmedica Business Overview
- 12.2.3 Addmedica Revenue in Sickle Cell Anemia Therapeutics Business (2021-2026)
- 12.2.4 Addmedica Sickle Cell Anemia Therapeutics Product Portfolio
- 12.2.5 Addmedica Recent Developments
- 12.3 Gamida Cell
- 12.3.1 Gamida Cell Company Information
- 12.3.2 Gamida Cell Business Overview
- 12.3.3 Gamida Cell Revenue in Sickle Cell Anemia Therapeutics Business (2021-2026)
- 12.3.4 Gamida Cell Sickle Cell Anemia Therapeutics Product Portfolio
- 12.3.5 Gamida Cell Recent Developments
- 12.4 GlycoMimetics
- 12.4.1 GlycoMimetics Company Information
- 12.4.2 GlycoMimetics Business Overview
- 12.4.3 GlycoMimetics Revenue in Sickle Cell Anemia Therapeutics Business (2021-2026)
- 12.4.4 GlycoMimetics Sickle Cell Anemia Therapeutics Product Portfolio
- 12.4.5 GlycoMimetics Recent Developments
- 12.5 Pfizer
- 12.5.1 Pfizer Company Information
- 12.5.2 Pfizer Business Overview
- 12.5.3 Pfizer Revenue in Sickle Cell Anemia Therapeutics Business (2021-2026)
- 12.5.4 Pfizer Sickle Cell Anemia Therapeutics Product Portfolio
- 12.5.5 Pfizer Recent Developments
- 12.6 Novartis
- 12.6.1 Novartis Company Information
- 12.6.2 Novartis Business Overview
- 12.6.3 Novartis Revenue in Sickle Cell Anemia Therapeutics Business (2021-2026)
- 12.6.4 Novartis Sickle Cell Anemia Therapeutics Product Portfolio
- 12.6.5 Novartis Recent Developments
- 12.7 Global Blood Therapeutics
- 12.7.1 Global Blood Therapeutics Company Information
- 12.7.2 Global Blood Therapeutics Business Overview
- 12.7.3 Global Blood Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2021-2026)
- 12.7.4 Global Blood Therapeutics Sickle Cell Anemia Therapeutics Product Portfolio
- 12.7.5 Global Blood Therapeutics Recent Developments
- 12.8 Micelle BioPharma
- 12.8.1 Micelle BioPharma Company Information
- 12.8.2 Micelle BioPharma Business Overview
- 12.8.3 Micelle BioPharma Revenue in Sickle Cell Anemia Therapeutics Business (2021-2026)
- 12.8.4 Micelle BioPharma Sickle Cell Anemia Therapeutics Product Portfolio
- 12.8.5 Micelle BioPharma Recent Developments
- 12.9 Bluebird Bio
- 12.9.1 Bluebird Bio Company Information
- 12.9.2 Bluebird Bio Business Overview
- 12.9.3 Bluebird Bio Revenue in Sickle Cell Anemia Therapeutics Business (2021-2026)
- 12.9.4 Bluebird Bio Sickle Cell Anemia Therapeutics Product Portfolio
- 12.9.5 Bluebird Bio Recent Developments
- 12.10 Prolong Pharmaceuticals
- 12.10.1 Prolong Pharmaceuticals Company Information
- 12.10.2 Prolong Pharmaceuticals Business Overview
- 12.10.3 Prolong Pharmaceuticals Revenue in Sickle Cell Anemia Therapeutics Business (2021-2026)
- 12.10.4 Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Product Portfolio
- 12.10.5 Prolong Pharmaceuticals Recent Developments
- 12.11 Modus Therapeutics
- 12.11.1 Modus Therapeutics Company Information
- 12.11.2 Modus Therapeutics Business Overview
- 12.11.3 Modus Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2021-2026)
- 12.11.4 Modus Therapeutics Sickle Cell Anemia Therapeutics Product Portfolio
- 12.11.5 Modus Therapeutics Recent Developments
- 12.12 Sangamo Biosciences
- 12.12.1 Sangamo Biosciences Company Information
- 12.12.2 Sangamo Biosciences Business Overview
- 12.12.3 Sangamo Biosciences Revenue in Sickle Cell Anemia Therapeutics Business (2021-2026)
- 12.12.4 Sangamo Biosciences Sickle Cell Anemia Therapeutics Product Portfolio
- 12.12.5 Sangamo Biosciences Recent Developments
- 12.13 Bioverativ
- 12.13.1 Bioverativ Company Information
- 12.13.2 Bioverativ Business Overview
- 12.13.3 Bioverativ Revenue in Sickle Cell Anemia Therapeutics Business (2021-2026)
- 12.13.4 Bioverativ Sickle Cell Anemia Therapeutics Product Portfolio
- 12.13.5 Bioverativ Recent Developments
- 12.14 Imara
- 12.14.1 Imara Company Information
- 12.14.2 Imara Business Overview
- 12.14.3 Imara Revenue in Sickle Cell Anemia Therapeutics Business (2021-2026)
- 12.14.4 Imara Sickle Cell Anemia Therapeutics Product Portfolio
- 12.14.5 Imara Recent Developments
- 12.15 Ironwood Pharmaceuticals
- 12.15.1 Ironwood Pharmaceuticals Company Information
- 12.15.2 Ironwood Pharmaceuticals Business Overview
- 12.15.3 Ironwood Pharmaceuticals Revenue in Sickle Cell Anemia Therapeutics Business (2021-2026)
- 12.15.4 Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Product Portfolio
- 12.15.5 Ironwood Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst